181 related articles for article (PubMed ID: 37614958)
21. Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.
Ruggiero A; Potestio L; Camela E; Fabbrocini G; Megna M
Psoriasis (Auckl); 2022; 12():127-137. PubMed ID: 35707807
[TBL] [Abstract][Full Text] [Related]
22. Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study.
Rigopoulos D; Angelakopoulos C; Apalla Z; Georgiou S; Delli F; Drosos A; Zafiriou E; Katsantonis J; Lazaridou E; Panagakis P; Papadavid E; Papakonstantis M; Roussaki-Schulze AV; Sotiriou E; Anastasiadis G; Tampouratzi E; Chasapi V; Sfaelos K; Ioannides D;
Dermatol Ther; 2022 Dec; 35(12):e15886. PubMed ID: 36184757
[TBL] [Abstract][Full Text] [Related]
23. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L
Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab.
Passeron T; Perrot JL; Jullien D; Goujon C; Ruer M; Boyé T; Villani AP; Quiles Tsimaratos N
JAMA Dermatol; 2024 Feb; 160(2):199-203. PubMed ID: 38054800
[TBL] [Abstract][Full Text] [Related]
25. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L; Ibba L; Malagoli P; Amoruso F; Argenziano G; Balato A; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Franchi C; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Maurelli M; Megna M; Orsini D; Sampogna F; Travaglini M; Valenti M; Costanzo A; Narcisi A
J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256629
[TBL] [Abstract][Full Text] [Related]
27. Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives.
Camiña-Conforto G; Mateu-Arrom L; López-Ferrer A; Puig L
Patient Prefer Adherence; 2023; 17():1541-1549. PubMed ID: 37408843
[TBL] [Abstract][Full Text] [Related]
28. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials.
Qiu Y; Zhu Y; Liu Y; Liu Q
J Dermatolog Treat; 2023 Dec; 34(1):2199106. PubMed ID: 37010492
[TBL] [Abstract][Full Text] [Related]
30. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC
Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881
[TBL] [Abstract][Full Text] [Related]
31. A Real-Life 208 Week Single-Centred, Register-Based Retrospective Study Assessing Secukinumab Survival and Long-Term Efficacy and Safety Among Greek Patients with Moderate to Severe Plaque Psoriasis, Including Difficult-to-Treat Manifestations Such as Genitals and Scalp.
Kyrmanidou E; Kemanetzi C; Stavros C; Trakatelli MG; Patsatsi A; Madia X; Ignatiadi D; Kalloniati E; Apalla Z; Lazaridou E
Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38810083
[TBL] [Abstract][Full Text] [Related]
32. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
[TBL] [Abstract][Full Text] [Related]
33. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
Caldarola G; Galluzzo M; Bernardini N; Calabrese L; Grimaldi M; Moretta G; Pagnanelli G; Shumak RG; Talamonti M; Tofani L; Pallotta S; Peris K; Potenza C; De Simone C; Campione E
Dermatol Ther; 2022 Jun; 35(6):e15488. PubMed ID: 35384168
[TBL] [Abstract][Full Text] [Related]
34. Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis.
Gao W; Yu B; Yan Y; Zhao L; Zhao R
Front Immunol; 2023; 14():1151977. PubMed ID: 37304299
[TBL] [Abstract][Full Text] [Related]
35. Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study.
Asahina A; Okubo Y; Morita A; Tada Y; Igarashi A; Langley RG; Deherder D; Matano M; Vanvoorden V; Wang M; Ohtsuki M; Nakagawa H
Dermatol Ther (Heidelb); 2023 Mar; 13(3):751-768. PubMed ID: 36648594
[TBL] [Abstract][Full Text] [Related]
36. Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study).
Chiricozzi A; Megna M; Giunta A; Carrera CG; Dapavo P; Balato A; Malagoli P; Mazzoccoli S; Parodi A; Sabatino S; Buzzoni C; Huang CH; Narcisi A
J Dermatolog Treat; 2023 Dec; 34(1):2246606. PubMed ID: 37587870
[TBL] [Abstract][Full Text] [Related]
37. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
38. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
Gargiulo L; Ibba L; Cascio Ingurgio R; Malagoli P; Amoruso F; Balato A; Bardazzi F; Brianti P; Brunasso G; Burlando M; Cagni AE; Caproni M; Carrera CG; Carugno A; Caudullo F; Cuccia A; Dapavo P; Di Brizzi EV; Dini V; Gaiani FM; Gisondi P; Guarneri C; Lasagni C; Licata G; Loconsole F; Marzano AV; Megna M; Mercuri SR; Musumeci ML; Orsini D; Ribero S; Ruffo Di Calabria V; Satolli F; Strippoli D; Travaglini M; Trovato E; Venturini M; Zichichi L; Valenti M; Costanzo A; Narcisi A
J Dermatolog Treat; 2024 Dec; 35(1):2350760. PubMed ID: 38714323
[TBL] [Abstract][Full Text] [Related]
39. Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study.
Ruggiero A; Fabbrocicni G; Cacciapuoti S; Potestio L; Gallo L; Megna M
Clin Cosmet Investig Dermatol; 2023; 16():529-536. PubMed ID: 36873660
[TBL] [Abstract][Full Text] [Related]
40. Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study.
Gargiulo L; Ibba L; Pavia G; Vignoli CA; Piscazzi F; Valenti M; Sanna F; Perugini C; Avagliano J; Costanzo A; Narcisi A
Dermatol Ther (Heidelb); 2022 Oct; 12(10):2309-2324. PubMed ID: 36063283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
